Chi Sheng Pharma & Biotech Co., Ltd

TPEX:4111 Rapporto sulle azioni

Cap. di mercato: NT$1.5b

Chi Sheng Pharma & Biotech Performance dei guadagni passati

Il passato criteri di controllo 2/6

Chi Sheng Pharma & Biotech has been growing earnings at an average annual rate of 13.9%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 2.3% per year. Chi Sheng Pharma & Biotech's return on equity is 6.1%, and it has net margins of 6.8%.

Informazioni chiave

13.9%

Tasso di crescita degli utili

13.9%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore18.5%
Tasso di crescita dei ricavi2.3%
Rendimento del capitale proprio6.1%
Margine netto6.8%
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

Apr 06
Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Mar 10
A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 01
Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Jan 05
Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Dec 10
Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Ripartizione dei ricavi e delle spese

Come Chi Sheng Pharma & Biotech guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

TPEX:4111 Ricavi, spese e utili (TWD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 241,0827326620
31 Mar 241,0657326221
31 Dec 231,0616926022
30 Sep 231,09011626523
30 Jun 231,11515126222
31 Mar 231,13016425420
31 Dec 221,14317924920
30 Sep 221,10518622718
30 Jun 221,08515021919
31 Mar 221,05912921919
31 Dec 211,02210821919
30 Sep 211,0035623319
30 Jun 219714123519
31 Mar 219534623119
31 Dec 209795922918
30 Sep 201,0057222819
30 Jun 201,0268022719
31 Mar 201,0478523420
31 Dec 191,0237223221
30 Sep 199985723322
30 Jun 199855723322
31 Mar 199644622922
31 Dec 189674222923
30 Sep 189855222724
30 Jun 181,0166022724
31 Mar 181,0326922223
31 Dec 171,0458221923
30 Sep 171,0349121320
30 Jun 171,0128820919
31 Mar 179958520919
31 Dec 169647320719
30 Sep 169464821025
30 Jun 169364620726
31 Mar 169384220325
31 Dec 159323920326
30 Sep 159084019120
30 Jun 159225018718
31 Mar 159255918419
31 Dec 149437317818
30 Sep 1497910417718
30 Jun 1497410517617
31 Mar 1496010617316
31 Dec 139219617116

Guadagni di qualità: 4111 has high quality earnings.

Margine di profitto in crescita: 4111's current net profit margins (6.8%) are lower than last year (13.6%).


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: 4111's earnings have grown by 13.9% per year over the past 5 years.

Accelerare la crescita: 4111's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Guadagni vs Settore: 4111 had negative earnings growth (-51.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.6%).


Rendimento del capitale proprio

ROE elevato: 4111's Return on Equity (6.1%) is considered low.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate